MORPHEUS CTS
ActiveSummary
MORPHEUS CTS has been active since 2019 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €322,239 and a net result of €127,793. Equity is growing by about 47% per year across the filed financial years. Its solvency ranks better than 49% of 4,319 sector peers (NACE 74, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
29-06
NBB filing
Annual accounts filed
financial year 2025 · micro format
2025
31-12
Financial
Highest result from 2019 to 2025net €127,793 ▲76.6%
Operating result €195,846, net result €127,793, both a record.
23-06
NBB filing
Annual accounts filed
financial year 2024 · micro format
2024
27-06
NBB filing
Annual accounts filed
financial year 2023 · micro format
2023
31-12
Financial
Equity above €200,000equity €301,670 ▲60.8%
A profit in every financial year since 2019 builds equity to €301,670.
15-06
NBB filing
Annual accounts filed
financial year 2022 · micro format
2022
31-12
Financial
Equity above €150,000equity €187,645 ▲82.9%
A profit in every financial year since 2019 builds equity to €187,645.
13-06
NBB filing
Annual accounts filed
financial year 2021 · micro format
2021
31-12
Financial
Equity above €100,000equity €102,615 ▲62.4%
A profit in every financial year since 2019 builds equity to €102,615.
16-06
NBB filing
Annual accounts filed
financial year 2020 · micro format
2020
31-12
Financial
Weakest financial yearnet €14,059 ▼67.2%
Net result drops to €14,059, the lowest in the series; recovery starts the following year.
01-07
NBB filing
Annual accounts filed
financial year 2019 · micro format
Financial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
0 of 2 deeds read
About the unread acts
We know of 2 Belgian Official Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.